Recursion Pharmaceuticals (RXRX) Citi's Biopharma Back to School Conference summary

Technology platform and data integration

• Developed a unified platform with thousands of models, hundreds of algorithms, and 65 petabytes of proprietary data, enabling advanced drug discovery and predictive modeling.

• Proprietary data collection and integrated architecture allow for sophisticated, validated predictions and continuous improvement of models.

• Focus on experimental validation and real-world data integration ensures robust model performance and reliability.

• Open-sourcing select tools, such as protein folding models, accelerates industry progress while core value remains in data specificity and model integration.

• Emphasis on a patient-first approach and internal experimentation differentiates from peers and supports scalable innovation.

Partnerships and business model

• Secured nearly $500 million from major partners like Roche and Sanofi, advancing multiple programs and achieving key milestones.

• Partnerships leverage unique technology, such as novel neural cell mapping and advanced chemistry design, to solve problems traditional methods cannot.

• Business development prioritizes deepening existing partnerships while remaining open to new collaborations, with a high bar for resource allocation.

• No plans for a SaaS or service-based model in the near term, maintaining control over platform evolution and complexity.

• Long-term strategy remains flexible, considering out-licensing or commercialization of internal pipeline assets as appropriate.

Clinical pipeline and validation

• Pipeline refocused post-merger, with no single lead program; all programs validated by both platform performance and clinical data.

• MEK1/2 inhibitor in FAP shows promising early results in reducing polyps and dysplasia, with further data expected before year-end.

• CDK7 program demonstrated accurate PK/PD predictions; combination study data anticipated to be more impactful.

• RBM39 and MALT1 programs target novel or improved mechanisms, with initial data and dose escalation results expected in the next year.

• Focus on high unmet needs and novel biology, avoiding incremental improvements in saturated markets.